Liu Yijuan, Wu Ting, Lu Dong, Zhen Jiantao, Zhang Lin
1 Department of Gastroenterology, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
2 Department of Gastrointestinal Surgery, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Int J Biol Markers. 2018 Aug;33(3):308-313. doi: 10.1177/1724600817746951. Epub 2018 Apr 23.
CD44 has recently been reported as a biomarker for pancreatic cancer. However, the predictive value of CD44 in pancreatic cancer remains controversial. Therefore, we performed this meta-analysis to evaluate the association between the expression of CD44 and clinicopathological features, and the outcome of pancreatic cancer patients.
A comprehensive literature search was performed using PubMed, Embase, and Chinese National Knowledge Infrastructure. The statistical analysis was conducted using Stata software.
A total of nine studies including 583 cases were included in this meta-analysis. The meta-analysis indicated that CD44 overexpression was associated with poor five-year overall survival rate (OR 0.52; 95% CI 0.30, 0.91; P = 0.02), more lymph node invasion (OR 3.14 (positive vs. negative); 95% CI 1.47, 6.73; P = 0.003), more advanced T stage (OR 2.4 (T3,4 vs. T1,2); 95% CI 1.28, 4.52; P = 0.007), and more advanced TNM stage (OR 4.53 (IIIIV vs. III); 95% CI 1.46, 14.08; P = 0.01). However, CD44 overexpression was not associated with other clinicopathological features, such as tumor size, differentiation, and distance metastasis.
The current evidence suggests that CD44 is an efficient prognostic factor in pancreatic cancer.
最近有报道称CD44是胰腺癌的生物标志物。然而，CD44在胰腺癌中的预测价值仍存在争议。因此，我们进行了这项荟萃分析，以评估CD44表达与临床病理特征之间的关联以及胰腺癌患者的预后。
使用PubMed、Embase和中国知网进行全面的文献检索。使用Stata软件进行统计分析。
本荟萃分析共纳入9项研究，包括583例病例。荟萃分析表明，CD44过表达与五年总生存率低相关（OR 0.52；95%CI 0.30，0.91；P = 0.02），淋巴结转移更多（OR 3.14（阳性vs.阴性）；95%CI 1.47，6.73；P = 0.003），T分期更晚（OR 2.4（T3,4 vs. T1,2）；95%CI 1.28，4.52；P = 0.007），以及TNM分期更晚（OR 4.53（IIIIV vs. III）；95%CI 1.46，14.08；P = 0.01）。然而，CD44过表达与其他临床病理特征无关，如肿瘤大小、分化程度和远处转移。
目前的证据表明，CD44是胰腺癌的一个有效的预后因素。
